You are here

Article Text

Article menu
Download PDFPDF
Miscellaneous
Lung alert
Diarylquinoline TMC207 as potential new therapy for multidrug-resistant tuberculosis
  1. E Tevendale
  1. Correspondence to Dr E Tevendale, CMT1, St James University Hospital, Leeds, UK; ewantevendale{at}nhs.net

https://doi.org/10.1136/thx.2009.122887

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    TMC207 is an investigational diarylquinoline which inhibits mycobacterial ATP synthase in drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro. It is bactericidal to dormant tubercle bacilli, therefore offering a new mechanism for the treatment of multidrug-resistant tuberculosis.

    This study is the first stage of a phase 2 randomised controlled trial. Conducted in South Africa, newly …

    View Full Text

    Footnotes

    • Provenance and Peer review Commissioned; not externally peer reviewed.